

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4515977

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	NSGENE A/S	03/23/2017
RECEIVING PARTY DATA		
Name:	HOBA THERAPEUTICS APS	
Street Address:	OLE MAALOES VEJ 3	
City:	COPENHAGEN	
State/Country:	DENMARK	
Postal Code:	2200	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	15589323
CORRESPONDENCE DATA		
Fax Number:	(502)585-2207	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	5025402372	
Email:	linda.hoggarth@dinsmore.com	
Correspondent Name:	LINDA J. HOGGARTH	
Address Line 1:	101 SOUTH FIFTH STREET	
Address Line 2:	SUITE 2500	
Address Line 4:	LOUISVILLE, KENTUCKY 40202	
ATTORNEY DOCKET NUMBER:	16HOBA-HO58503NA	
NAME OF SUBMITTER:	WESTON R. GOULD	
SIGNATURE:	/Weston R. Gould/	
DATE SIGNED:	07/23/2017	
Total Attachments: 2		
source=15589323_Assignment#page1.tif		
source=15589323_Assignment#page2.tif		

ASSIGNMENT

WHEREAS, **NsGENE A/S**, a corporation of Denmark, with a place of business at Baltorpvej 154, 2750 Ballerup, Denmark (hereinafter referred to as Assignor), is the owner of the entire right, title and interest in and to the invention entitled **Therapeutic Use of a Growth Factor, METRNL**, under

- ☒ Patent Application Serial No. 14/721,165
- ☒ U.S. Patent No. 8,334,264
- ☒ U.S. Patent No. 9, 068,015

AND WHEREAS, **HOB A THERAPEUTICS ApS**, a corporation of Denmark, having its principal office at Ole Maaløes Vej 3, 2200 Copenhagen, Denmark (hereinafter called the Assignee), is desirous of acquiring the entire right, title and interest in and to the above application and patents and the inventions therein claimed and any letters patent that may issue thereon;

NOW, THEREFORE, for good and valuable consideration, receipt whereof is hereby acknowledged, we hereby sell, assign and transfer unto said Assignee, its successors and assigns, the entire right, title and interest in and to said patents and said application and any divisions or continuations thereof, and the inventions therein disclosed, and any improvements thereon, and any patent or patents that may be issued or reissued thereon, and we hereby authorize and request the Commissioner of Patents and Trademarks to issue any letters patent thereon, and reissues thereof, to said Assignee, its successors and assigns; and we hereby authorize said Assignee, its successors and assigns, to file in its own name applications for patent in foreign countries in connection with the inventions hereby transferred, under the International Convention claiming the priority of said United States application or otherwise, and to secure in its own name the patent or patents issued thereon; and we hereby agree that, upon request, we will sign all papers, and make all rightful oaths, and do all acts which said Assignee, its successors or assigns, may consider necessary in connection with said United States patents and application, and in connection with any other United States or foreign applications that may be filed in connection with said inventions, and with any improvements thereon, and in connection with any patents issued or reissued thereon.

IN WITNESS WHEREOF, said Assignor has caused these presents to be signed by its duly authorized officer below named this 23rd day of March, 2017.

NsGENE A/S

By Søren S. Skjærbæk

Name Søren S. Skjærbæk

Title Liquidator

Anita Milland 23 March 2017

WITNESS

DATE

Anita Milland